Cambridge, United States
Flare Therapeutics, founded in 2021, is trailblazing the path to drugging transcription factors to discover precision medicines for cancer and other disease areas. This United States-based company is strategically positioned in the biopharma, biotechnology, health care, and life sciences industries.
The company's unique value proposition revolves around its targeted approach to drugging transcription factors, a sector of the proteome that has traditionally been difficult to target. By leveraging their integrated discovery platform, Flare Therapeutics uncovers novel validated ligands, significantly advancing its efforts in precision medicine.
Their lead program, FX-909, displays promise as a first-in-class orally available small molecule for PPARG, with confirmed clinical proof-of-concept in urothelial cancer. The second lead program, FX-111, aims to selectively degrade ARON.
In March 2023, Flare Therapeutics secured a significant $123.00M Series B investment. Key investors include Casdin Capital, Novartis, Third Rock Ventures, and Pfizer Ventures, among others, signaling robust confidence in their innovative approach.
